Home Blog Page 20
Chairman Joseph C. Papa and CFO Paul Herendeen of Bausch Health Companies (NYSE:BHC) purchased a total of 40,000 BHC shares on Sept. 14 at an average price of $22.39, spending $896,000. And thanks to a “Matching Share Program” offered by Bausch Health, the insiders were granted an additional 40,000 shares. The granted shares are restricted – 1/3 of the granted shares vest on each of the three anniversaries of the date granted. If the insider leaves the company, he or she would forfeit unvested shares.
Insider buying and large 13F increases don’t always immediately translate into higher stock prices. A case in point is the development-stage biotech company Pfenex Inc. (AMEX:PFNX).
Paul S Levy, Chairman of the Board at Builders FirstSouce Inc. (Nasdaq:BLDR) significantly increased his stake in the building products manufacturer by 10%, buying 100,000 shares on Sept. 6 on the open market at $15.98. According to a Form 4 filed with the SEC on Sept. 7, Levy increased his stake to 1,117,984 shares or about 1% of BLDR’s shares outstanding.
A recent example of how insider trading analysis can support biotech investing decisions is the case of Sangamo Therapeutics (Nasdaq: SGMO). In the two trading days following a September 4 release of data from a clinical trial, SGMO shares of fell over 31%.
Jab Holdings B.V. disclosed via Form 4 filings on August 28 buying over $32 million of Coty Inc. (NYSE:COTY) shares at prices ranging from $11.98 to $12.90 on August 24 through August 28. Last December 31 JAB filed a 13G disclosing a 76% stake in the beauty company. Since filing the 13G at years end, JAB has acquired an additional 30 million shares of COTY spending nearly $83 million dollars.
Just over a year ago Hurricane Maria devastated the northern Caribbean, causing catastrophic damage and loss of life across the region and particularly in Puerto Rico. For Liberty Latin America (Nasdaq:LILA), a leading provider of cable, internet and telephone services in Puerto Rico and nearby islands, it’s taken a long time to restore service, and the company’s operations and stock price have suffered.
Whether they’re called penny stocks, micro-caps, OTC stocks or “lottery tickets,” low-priced, illiquid stocks of small companies have a bad reputation with many investors. Unquestionably micro-cap stocks can be illiquid, risky and highly speculative. Nonetheless, Hedge Funds can and do hold lots of micro-caps.
Marijuana stocks may finally be getting some respect from professional investors. Funds holding stock in Ontario-based marijuana producer Canopy Growth (NYSE:CGC) increased their holdings massively in the 2nd quarter. In Q1 2018, CGC comprised a total of 1.69% of all 13F portfolios holding the stock. In the 2nd quarter that number jumped to 31.30%
Acuta Capital Partners, LLC rode a surge in health care stock prices to the top spot in 2nd quarter hedge fund performance.
The dubious distinction of worst hedge fund performance in the 2nd quarter -- based on equal weightings of 13F positions -- goes to Tiger Pacific Capital LP. An equal weighting of the fund’s 14 positions returned -21.69% in the quarter, according to WhaleWisdom.com